Meiji Yasuda America Inc Makes New $3.06 Million Investment in Gilead Sciences, Inc. $GILD

Meiji Yasuda America Inc purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 24,934 shares of the biopharmaceutical company’s stock, valued at approximately $3,060,000.

A number of other institutional investors have also recently bought and sold shares of the business. Nuveen LLC boosted its stake in Gilead Sciences by 6.2% during the fourth quarter. Nuveen LLC now owns 6,314,056 shares of the biopharmaceutical company’s stock worth $774,987,000 after buying an additional 368,303 shares in the last quarter. Xponance LLC boosted its stake in Gilead Sciences by 5.6% during the fourth quarter. Xponance LLC now owns 237,491 shares of the biopharmaceutical company’s stock worth $29,150,000 after buying an additional 12,516 shares in the last quarter. Canopy Partners LLC boosted its stake in Gilead Sciences by 5.4% during the fourth quarter. Canopy Partners LLC now owns 3,455 shares of the biopharmaceutical company’s stock worth $424,000 after buying an additional 177 shares in the last quarter. Keel Point LLC boosted its stake in Gilead Sciences by 24.1% during the fourth quarter. Keel Point LLC now owns 7,472 shares of the biopharmaceutical company’s stock worth $917,000 after buying an additional 1,449 shares in the last quarter. Finally, Wescott Financial Advisory Group LLC boosted its stake in Gilead Sciences by 3.4% during the fourth quarter. Wescott Financial Advisory Group LLC now owns 3,668 shares of the biopharmaceutical company’s stock worth $450,000 after buying an additional 122 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of recent research reports. Citigroup lifted their price target on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Wolfe Research lifted their price target on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Wall Street Zen downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Leerink Partners reduced their target price on shares of Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a research note on Monday, February 23rd. Twenty-five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $156.93.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the completion of the sale, the chief executive officer directly owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. The trade was a 2.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the sale, the chief financial officer directly owned 173,191 shares of the company’s stock, valued at $22,907,973.57. This represents a 1.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 68,000 shares of company stock worth $9,047,570 in the last 90 days. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Up 3.6%

Shares of NASDAQ GILD opened at $125.87 on Friday. The firm’s 50-day simple moving average is $133.46 and its 200 day simple moving average is $134.34. The company has a market cap of $156.28 billion, a price-to-earnings ratio of 17.15 and a beta of 0.31. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 12-month low of $104.46 and a 12-month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. The business had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.6%. Gilead Sciences’s dividend payout ratio is 44.69%.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Bernstein initiated/maintained a Buy view on Gilead, adding to the bullish analyst sentiment around the stock. Gilead Sciences (GILD) Gets a Buy from Bernstein
• Positive Sentiment: Gilead and Merck reported positive topline Phase 3 results for their once-weekly oral HIV regimen (islatravir + lenacapavir), which strengthens the company’s growth story and HIV franchise outlook. Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now?
• Positive Sentiment: Gilead’s HIV business continues to get attention for momentum from Biktarvy, Descovy, and Yeztugo, with late-stage pipeline progress supporting the long-term earnings outlook. Can Gilead Sciences HIV Franchise Drive Long-Term Growth?
• Positive Sentiment: Recent Phase 3 IDEAL study results for Livdelzi in primary biliary cholangitis also reinforced confidence in Gilead’s pipeline development. Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development
• Neutral Sentiment: Gilead was cited in broader articles about pharma/biotech M&A and healthcare investing, which may keep the stock on traders’ radar but does not directly change fundamentals. Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
• Neutral Sentiment: Unusually heavy call-option activity suggests traders are positioning for more upside, though it is not a fundamental development.
• Neutral Sentiment: Gilead Foundation’s ~$3 million HIV/AIDS education commitment is positive for brand and ESG perception, but the financial impact is likely limited. National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.